Total testosterone levels are correlated to metabolic syndrome components

Blaya, Rodrigo; Thomaz, Leonardo Dalla Giacomassa Rocha; Guilhermano, F.F.; Paludo, Artur de Oliveira; Rhoden, Luiza; Halmenschlager, Graziele; Rhoden, Ernani Luı́s

doi:10.3109/13685538.2016.1154523

Cited by 49 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The importance of aromatase activity in Met S requires further investigation. These findings may have implications for the assessment of cardiometabolic risks in older and obese men [60]. The aforementioned studies strongly suggest that low TT levels independently predict Met S and the number of Met S components are inversely correlated with TT levels.…”

Section: Introductionmentioning

confidence: 98%

“…As shown in Table 1, a considerable body of literature exists demonstrating a bidirectional link between TD and Met S [23441424344454647484950515253545556575859606162]. Several systematic reviews, crosssectional studies, and clinical trials have reported low levels of total T (TT) and sex-hormone binding globulin (SHBG) in men with Met S, irrespective of age [11446364].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…Increased body mass index (BMI) is thought to be a sign of elevated body fatness, which may cause cardiometabolic and atherosclerotic diseases (Lovren, Teoh, & Verma, ; Xu et al, ). Although the relationship between obesity and ED has not yet been fully elucidated, obesity and metabolic syndrome (MS) are known to deteriorate the synthesis of nitric oxide (NO) in the vascular bed, decrease in plasma testosterone levels, endothelial dysfunction, and dyslipidaemia, all contributing to the pathophysiology of sexual dysfunction (Blaya et al, ).…”

Section: Introductionmentioning

confidence: 99%

Visceral adiposity index is useful for evaluating obesity effect on erectile dysfunction

et al. 2019

View full text Add to dashboard Cite

Studies show that erectile dysfunction (ED) is associated with obesity, and it has been shown that the possibility of developing sexual dysfunction in obese men is 30% higher compared to those with normal weight. Obesity is measured using various methods, for example waist circumference (WC) measurement or body mass index (BMI), but recently, visceral adiposity index (VAI) has also been utilised to better assess obesity and metabolic syndrome. In our study, the potential link between VAI and ED was investigated. The data of 176 patients who presented to the urology outpatient clinic with erection complaints were retrospectively screened. A control group was also established with 122 men without complaints of erectile dysfunction. The erectile functions of all participants were determined using the International Erectile Function Index‐5 (IIEF‐5) scoring. In addition, their serum fasting blood glucose, total testosterone (TT), triglyceride (TG), low‐density lipoprotein (LDL) cholesterol and high‐density lipoprotein (HDL) cholesterol levels were measured. The physical examination comprised the measurement of WC, height and weight, and BMI. The mean age of the participants was 58.7 ± 8.4 for the ED group and 57.1 ± 7.5 for the control group. The mean VAI was statistically significantly higher in the ED group (5.32 ± 2.77) compared to the control group (4.11 ± 1.93) (p < 0.001). Since VAI contains both physical and metabolic parameters, our findings suggest that it discloses the effects of WC, BMI, HDL and TG more clearly. VAI is considered useful for the assessment of the effect of obesity on ED patients.

show abstract

“…Although the literature data provide evidence on the connection of LOH in patients with metabolic syndrome and its components, i.e. adiposity or dyslipidaemia (Blaya et al, 2016), as well as the connection of testosterone deficiency with cardiovascular diseases and mortality risk (Lester and Mason, 2015), there have been too limited data on the prevalence of hypogonadism in patients with arterial hypertension until now. The European Male Ageing Study (launched in 2003) investigated health, chronic diseases, and the level of sex steroids in over 3000 men in the age group of 40 to 79 years.…”

Section: Discussionmentioning

confidence: 99%

Detection of Late-Onset Hypogonadism in Men with Chronic Internal Diseases

Požarskis

Lejnieks

2019

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

View full text Add to dashboard Cite

Late-onset hypogonadism (LOH) is a clinical and biochemical syndrome associated with age and featured by typical symptoms and reduced blood testosterone level. Among males aged over 30 years, the incidence of androgen deficiency is 7 to 30%. The aim of this study was to investigate the incidence of hypogonadism in patients aged over 40 years with an underlying condition and/or a comorbidity, such as arterial hypertension, Chronic obstructive pulmonary disease (COPD), metabolic syndrome, Type 2 of diabetes mellitus, dyslipidaemia, adiposity in various General practice (GP) and physician-sexologists’ offices in Latvia, and to determine the influence of chronic diseases on the development of hypogonadism. Males aged 39 years who turned to family doctors at nine GP were offered to fill in Aging Male Study (AMS) questionnaires used for the diagnostics of late-onset hypogonadism. Males aged 40 years who visited the office of the physician sexologist Anatolijs Požarskis were offered to fill in the same questionnaires. After compiling the data from AMS questionnaires, a group of males exhibiting signs of LOH were isolated (in total 1222 persons). In these patients, we determined blood testosterone and sex-hormone binding globulin (SHBG) levels. Chronic diseases were found in these men in data evaluation of patient medical records, and after performing physical and laboratory examinations. Late-onset hypogonadism was laboratory-diagnosed in 79% of patients with signs of late-onset hypogonadism in accordance with the AMS questionnaires and with concomitant diseases and in 4.7% of patients with signs of late-onset hypogonadism in accordance with the AMS questionnaires and without the aforementioned concomitant diseases. Persons with arterial hypertension, dyslipidaemia, adiposity, metabolic syndrome, COPD and Type 2 of diabetes mellitus had higher chance of developing hypogonadism (p < 0.001). Arterial hypertension, dyslipidaemia, adiposity, metabolic syndrome, COPD statistically significantly (p < 0.001) decreased the level of total testosterone by 0.47, 1.18, 0.36, 0.67, and 0.18 ng/ml, respectively, and decreased the level of free testosterone by 2.52, 2.71, 1,69, 6.77, and 4.58 pg/ml, respectively. Type 2 diabetes mellitus had no statistically significant effect on the level of total and free testosterone (p = 0.95, p = 0.10). The most significant decrease in the level of testosterone was observed in cases of dyslipidemia, COPD and metabolic syndrome. General physicians should pay special attention to patients with this disease, as these patients belong to a group with a high risk of development of expressed LOH syndrome.

show abstract

Total testosterone levels are correlated to metabolic syndrome components

Abstract: Low TT levels were associated with MetS diagnosis. Abdominal obesity was the MetS component independently correlated to low TT levels.

Cited by 49 publications

References 28 publications

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Visceral adiposity index is useful for evaluating obesity effect on erectile dysfunction

Detection of Late-Onset Hypogonadism in Men with Chronic Internal Diseases

Contact Info

Product

Resources

About